Breaking News

Financial Report: InterMune

May 2, 2014

Esbriet revenues climb 188%


1Q Revenues: $30.3 million (+188%)

1Q Loss: $53.6 million (loss of $49.9 million in 1Q13)

Comments: Esbriet revenue in the quarter was $30.3 million, up 188%. R&D expenses were $32.1 million, up 24%, attributed to activities to complete the ASCEND Phase III trial, a higher number of patients in the RECAP extension study of pirfenidone, and activities related to the pirfenidone NDA resubmission.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision